Quick Answer
Calidi Biotherapeutics, Inc. reported Research And Development Expense of $9.74 million for the year ending 2025.
- Calidi Biotherapeutics, Inc. showed an increase of +9.7% in Research And Development Expense from 2024 to 2025.
- This data is from Calidi Biotherapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 27, 2026.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2022: $1.95 million | Q1 2023: $2.62 million | Q2 2023: $3.18 million | Q3 2023: $3.25 million | Q1 2024: $2.74 million | Q2 2024: $2.17 million | Q3 2024: $2.15 million | Q1 2025: $2.43 million | Q2 2025: $2.59 million | Q3 2025: $2.36 million.
- Over the full 4 years of available data (2022 to 2025), Calidi Biotherapeutics, Inc.'s Research And Development Expense has grown by 34.2%.
- Historical annual values: Fiscal year 2025: $9.74 million | Fiscal year 2024: $8.88 million | Fiscal year 2023: $13.01 million | Fiscal year 2022: $7.26 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: